Chief Executive Officer | Medexec
Request Services
Industry Medical Devices
Location Europe
Employees 370

The Project

Medexec was retained by a global mid-sized medical device manufacturer to appoint a new CEO following the planned retirement of their long-standing leader.

The company specialised in minimally invasive surgical technologies with a strong footprint across Europe and Asia-Pacific, and ambitions to scale further into North America and the Middle East.

The incoming CEO would be responsible for:

  • Evolving the global strategy to compete in a highly regulated, innovation-driven market

  • Building commercial capabilities across new markets

  • Driving operational excellence and R&D alignment

  • Leading future M&A activity and potential exit planning

The ideal candidate profile included:

  • A proven CEO or senior P&L leader within the medical devices sector

  • Deep understanding of global regulatory landscapes (EU MDR, FDA, APAC compliance)

  • Experience scaling product portfolios across diverse international markets

  • A track record of building high-performing, cross-functional teams

Our Recommendation

  • Conduct a global search strategy across EMEA, North America, and Asia-Pacific.
  • Act as a trusted advisor to the board throughout, aligning stakeholders across regions and time zones.

Map and engage senior talent from:

  • Mid-cap and large-cap medical device manufacturers

  • Scale-ups with innovative IP in minimally invasive or diagnostics technologies

Focus on candidates with:

  • Board-level leadership and global P&L accountability

  • Proven success in navigating regulatory complexity across multiple jurisdictions

  • A strong mix of commercial drive, technical credibility, and cultural agility

Results Delivered

  • CEO appointed within 10 weeks.

The successful candidate brought:

  • 20+ years in the MedTech sector, including as CEO of a €100M turnover surgical devices company

  • Experience leading market entry in North America and APAC

  • Strong relationships with regulatory bodies and clinical communities

The appointment positioned the business for its next growth phase and planned strategic exit.